News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Rejects Novartis AG (NVS) Asthma Drug in Change of Tack


11/9/2012 7:41:46 AM

Britain's health cost-effectiveness watchdog NICE plans to recommend against the use of Novartis's severe asthma drug Xolair, or omalizumab, after earlier endorsing it for adults only. The National Institute for Health and Clinical Excellence (NICE), which decides if medicines should be given on the state health service, said on Friday it had changed its mind in the light of evolving clinical evidence. "After considering new evidence that has become available since the original guidance was published - particularly new mortality data - the NICE draft guidance does not recommend omalizumab for either adults or children," NICE said.

Read at Reuters
Read at WebMD
Read at Pharma Times [Free Reg Req'd]


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES